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Among patients with tuberculosis and human immunodeficiency virus type 1, CD4-stratified initiation of antiretro-
viral therapy (ART) is recommended, with earlier ART in those with low CD4 counts. However, the impact of imple-
mentation fidelity to this recommendation is unknown.We examined a prospective cohort study of 395 adult patients
diagnosed with tuberculosis and human immunodeficiency virus between August 2007 and November 2009 in
Kinshasa, Democratic Republic of the Congo. ART was to be initiated after 1 month of tuberculosis treatment at a
CD4 count of <100 cells/mm3 or World Health Organization stage 4 (other than extrapulmonary tuberculosis) and
after 2months of tuberculosis treatment at a CD4 count of 100–350 cells/mm3.We used the parametric g-formula to
estimate the impact of implementation fidelity on 6-month mortality. Observed implementation fidelity was low
(46%); 54% of patients either experienced delays in ART initiation or did not initiate ART, which could be avoided
under perfect implementation fidelity. The observedmortality risk was 12.0% (95% confidence interval (CI): 8.2, 15.7);
under complete (counterfactual) implementation fidelity, the mortality risk was 7.8% (95% CI: 2.4, 12.3), correspond-
ing to a risk reduction of 4.2% (95%CI: 0.3, 8.1) and a preventable fraction of 35.1% (95%CI: 2.9, 67.9). Strategies to
achieve high implementation fidelity to CD4-stratified ART timing are needed to maximize survival benefit.
antiretroviral therapy; causal inference; HIV; human immunodeficiency virus; implementation fidelity; parametric
g-formula; tuberculosis
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IQR, interquartile range;
ITART, Integrating Tuberculosis and Antiretroviral Treatment; OR, odds ratio; TB, tuberculosis; WHO, World Health Organization.
In 2012, an estimated 1.1 million (14%) of the 8.6 million
patients diagnosed with active tuberculosis (TB) disease
worldwide were also infected with human immunodeficiency
virus (HIV) (1). Although, under current World Health Orga-
nization (WHO) guidelines, all people diagnosed with TB
and HIV are eligible for antiretroviral therapy (ART), only
57% initiated ART during TB treatment in 2012 (1). Findings
from randomized controlled trials demonstrated that early
ART, defined as within 2–4 weeks of start of TB treatment,
reduces mortality in patients with a CD4 count of <50 cells/
mm3. In these trials, early ART initiation did not result in sta-
tistically significant lower mortality in patients with CD4
counts of >50 cells/mm3 (2–4). On the basis of these find-
ings, the WHO recommends ART initiation within 2 weeks
of TB treatment for patients with a CD4 count of <50 cells/
mm3 and within 8 weeks for all people diagnosed with HIV
and TB (5).
Findings from randomized controlled trials are not always
replicable in less strictly controlled settings. Observational
studies from sub-Saharan Africa have found that most pa-
tients initiate ART late, after 8 weeks of TB treatment (6–
10). Lack of integration of TB and HIV treatment services has
been identified as one of the key contributors to this delay
(9, 10). Interventions to integrate TB and HIV services have
been shown to reduce, but not eliminate, delay in ART initi-
ation (11, 12).
Implementation fidelity, defined as the degree to which an
intervention is implemented as intended, is a potential modifier
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of the relationship between an intervention and its intended
outcome and is important to translation of evidence-based
recommendations into clinical practice (13, 14). Achieving
high implementation fidelity can help to replicate the success
an intervention has achieved in randomized controlled trials
(13). The relatively low coverage of timely ART initiation in
patients with TB suggests that implementation fidelity to the
2012 WHO guidelines for timing of ART initiation in TB pa-
tients may be a challenge in routine clinical settings, even with
integrated HIV/TB treatment. Data on implementation fidelity
in resource-limited settings and its impact on desired outcomes
are limited.
We aimed to quantify the impact of implementation fidel-
ity to CD4-stratified timing of ART initiation for TB patients
on mortality in a prospective cohort of patients receiving inte-
grated TB/HIV treatment at the primary care level in Kinshasa,
Democratic Republic of the Congo.
METHODS
Setting, study population, and study procedures
The Integrating Tuberculosis and Antiretroviral Treatment
(ITART) Study was conducted at 5 primary health clinics in
the Democratic Republic of the Congo and enrolled patients
between August 2007 and November 2009 (15). All patients
diagnosed with HIV and TB per national Democratic Repub-
lic of the Congo guidelines were offered study participation;
3 refused. At baseline, relevant demographic and clinical data
were collected, and CD4 count testing was performed.
Study nurses (1 per clinic) were trained to implement a
CD4-stratified timing strategy for ART initiation in accord
with the 2006 WHO guidelines. Patients were eligible to ini-
tiate ART at completion of the first month of TB treatment if
the baseline CD4 count was below 100 cells/mm3 or WHO
stage 4 condition other than extrapulmonary TB, as well as at
2 months of TB treatment if the baseline CD4 count was be-
tween 100 and 350 cells/mm3. Patients with a baseline CD4
count of >350 cells/mm3 were scheduled for repeat CD4 test-
ing at month 5 of TB treatment and were eligible to initiate
ART at the end of TB treatment if the CD4 count had dropped
to ≤350 cells/mm3 or when an incident WHO stage 4 condi-
tion occurred. When CD4 counts were not available (because
of a shortage of reagents), all patients were considered eli-
gible for ART initiation at 1 month. According to the legal
framework of the Democratic Republic of the Congo, nurses’
decisions to initiate ART needed approval by a consulting
physician. Providers assessed whether the patient was or was
not tolerating TB treatment at the time of ART eligibility on
the basis of clinical judgment as the 2006 WHO guidelines
did not definewhat constitutes tolerance (or intolerance) ofTB
treatment.
Patients were seen by study nurses weekly during the 2-
month intensive phase, monthly during the subsequent 4-
month continuation phase, and at completion of TB treatment.
Patients were considered lost to follow-up if they were more
than 3 days late for a scheduled clinic visit and could not be
located by phone or home visit.
The ITART Study was approved by institutional review
boards at both the University of North Carolina at Chapel
Hill and the University of Kinshasa. All patients provided
written informed consent for participation in the study.
Study population and definitions
This analysis was limited to individuals aged ≥13 years
who were enrolled in the ITART Study within 1 month of
TB treatment start, were treated with ART, were naïve, and
had a CD4 count of ≤350 cells/mm3 within 30 days of the
start of TB treatment (at baseline).
Outcome
Mortality was defined as all-cause mortality during the first
6 months of TB treatment, the duration of first-line TB treat-
ment. Using the standard approach for observational cohort
studies, we calculated the 6-month risk of mortality on the
basis of the observed outcomes. Patients who were lost to
follow-up prior to 6 months were assigned amissing outcome
and did not contribute to the numerator or denominator of the
observed risk.
Risk factors for mortality
We used a logistic regression model to assess baseline co-
variates, including the timing of ART initiation, as potential
predictors of mortality. We first ran a full logistic model con-
taining all the by selected covariates. Subsequently, we used
a backwards elimination stepwise method to generate a final
(reduced) predictivemodel. Covariates were assessed in order
from the highest to the lowest Wald χ2 and eliminated from
the model by using the likelihood ratio test with an α = 0.10.
We estimated crude and adjusted odds ratios with 95% con-
fidence intervals.
Assessment of implementation fidelity
“Implementation fidelity” is defined as the degree to which
programs are implemented as intended, with a focus on con-
tent or frequency of the intervention (13). In this study, we
confined implementation fidelity to the CD4-stratified ART
initiation strategy as the proportion of individuals who initi-
ated timely ART, that is, according to a priori–defined CD4
criteria.We calculated each patient’s timing of ART initiation
by comparing the ART start date with the TB treatment start
date. We categorized the timing of ART initiation as per
CD4-stratified strategy (“per strategy”) or deviating from
CD4-stratified strategy (“not per strategy”). To accommodate
a combination of scheduling limitations, clinic closures on
weekends and holidays, and limited availability of a consult-
ing physician as required for ART initiation per the Demo-
cratic Republic of the Congo legal framework, a 5-day grace
period was added to the 1- or 2-month TB treatment to define
ART initiation per strategy. Participants who initiated ART
prior to the time they became eligible plus 5 days were cate-
gorized as per strategy. Participants who died or were lost to
follow-up prior to eligibility for ART and had not initiated
ARTwere categorized as initiatingARTper strategy, since not
initiating ART prior to death or loss to follow-up did not con-
stitute deviation from the CD4-stratified strategy. In sensitivity
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analyses, we explored the impact of narrowing the definition of
ART initiation per strategy to exclude patients whowere lost to
follow-up prior to the time of ART eligibility, a subset of pa-
tients who could have started timely ART had they been re-
tained in care.
Differences in the proportions andmedians of baseline char-
acteristics between patients initiating ART per strategy and
those initiating not per strategy were assessed by using χ2 or
Fisher’s exact tests and Kruskal-Wallis tests, respectively.
Estimation of the causal effect of implementation fidelity
on mortality
To estimate the causal effect of implementation fidelity, we
compared mortality in the study population under observed
intervention fidelity with mortality in the study population
with complete implementation fidelity (Figure 1) (16, 17).
Standard multivariable regression would not easily allow us
to estimate the difference in risk in mortality at the population
level attributable to implementation fidelity. We overcame
this by using the parametric g-formula to estimate mortality
in the cohort under the counterfactual scenario of complete
implementation fidelity (18–20). A step-by-step overview of
this methodological approach is presented in Appendix 1,
and the worked example is presented as Appendix 2 (18).
We built a logistic regression model to assess the associa-
tion between initiating ART per strategy and mortality (step
1), including baseline covariates identified as potential con-
founders using a directed acyclic graph. We then used param-
eter estimates from the model to calculate the predicted
probability of death for each patient based on their baseline
covariates and observed ART timing (step 2). This modeling
method imputes an outcome for each patient on the basis of
the average risk across patients with observed outcomes with
the same baseline characteristics. Consequently, the outcome
of participants who were lost to follow-up is no longer miss-
ing, as these participants are assigned an outcome on the basis
of their baseline characteristics. By averaging these predicted
probabilities of death across all participants, we estimated the
risk of mortality in the full cohort under the observed, real-
life level of implementation fidelity (step 3).
To estimate the causal effect of implementation fidelity, we
estimated a (counterfactual) probability of death for each par-
ticipant, corresponding to what would have happened to each
participant had he or she initiated ART per strategy. For par-
ticipants who did initiate ART per strategy, this predicted
probability of death is the same as that calculated in step 2; for
participants who did not initiate ART per strategy, we estimat-
ed this probability based on the outcomes of patientswith sim-
ilar baseline characteristics who did initiate ART per strategy
(step 4). By averaging these predicted probabilities, we esti-
mated the risk of mortality in the full cohort under a scenario
of complete (100%) implementation fidelity (step 5).
We then calculated the risk difference by subtracting this
mortality risk estimate in the cohort with complete fidelity
from the mortality risk estimate in the cohort with observed fi-
delity (step 6). Bootstrappingwas used to generate the 95% con-
fidence interval around the risk difference. This was done by
creating multiple (n = 500) data sets through random selection
of 395 individuals with replacement from the original ITART
Study population, followed by rerunning step 1 through step
6, and using the standard error across all the risk difference es-
timates (step 7).
We estimated the preventable fraction similarly, by divid-
ing the risk difference by the estimated risk in the cohort
under observed, real-life implementation fidelity and boot-
strapping the corresponding 95% confidence interval. This
measure is interpreted as the fraction of mortality that could
be prevented if 100% implementation fidelity were achieved.
RESULTS
Baseline characteristics of the analytical cohort
Between August 2007 and November 2009, 599 partici-
pants enrolled in the ITART Study. Among them, 204 were
sequentially excluded on the basis of age <13 years (n = 18),
lack of baseline CD4 count (n = 88), enrollment more than 1
month after TB treatment initiation (n = 1), exposure to ART
prior to enrollment (n = 0), and CD4 count >350 (n = 97).
The remaining 395 participants were included in the analysis.
Baseline characteristics of the patients are presented in
Table 1. The typeofTBwas smear-positive pulmonary in 35%,
smear-negative pulmonary in 45%, and extrapulmonary in
20% of patients. Just over half (59%) were female, and the me-
dian agewas 38 (interquartile range (IQR), 32–45) years. Most
patients were underweight (median body mass index (weight
(kg)/height (m)2), 17.8; IQR, 16.5–19.7); 59.2% had a body
mass index of <18.5. Patients presented late in the HIV disease
process, with a median CD4 count of 131 cells/mm3 (IQR, 63–
224). Of the 143 (36%) patients eligible for ARTat 1month, 77
(54%) had a CD4 count of <50 cells/mm3, 64 (45%) had a CD4
count of 50–99 cells/mm3, and 2 (1%) had a CD4 count of
>100 cells/mm3 andWHO stage 4. Of the 252 (64%) patients
eligible for ART at 2 months, 136 (54%) had a CD4 count of
Assigned Timing





Figure 1. Impact on mortality of perfect versus observed implemen-
tation fidelity to CD4-stratified timing of antiretroviral therapy (ART),
Integrating Tuberculosis and Antiretroviral Treatment Study, 2007–
2009. All individuals were assigned to the timing per protocol (top,
all black), but only 44%were observed to adhere to timing per protocol
(middle; diagonal lines represent nonadherence to protocol). In anal-
ysis, we wished to understand the difference between what was
observed (bottom, left) and the counterfactual exposure distribution
in which all subjects adhered to timing per protocol (bottom, right).
Note that probability of outcome (mortality) is not explicitly shown in
these figures.
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100–199 cells/mm3 and 116 (46%) had a CD4 count of 200–
350 cells/mm3. A few patients (n = 24) (6%) had a contrain-
dication to 1 or more antiretroviral drugs.
Implementation fidelity to CD4-stratified timing of ART
initiation
Overall, 183 (46%) participants initiated ART per strategy.
Among the 212 (54%) participants who initiated ART not per
strategy, 53 (25%) never initiated ART, and 159 (75%) initi-
ated ARTwith a median delay of 11 days (IQR, 4–24) beyond
the time of eligibility plus 5 days. The median delay did not
differ by eligibility category (12 days for those eligible
at 1 month vs. 10 days for those at 2 months) (P = 0.62).
Patients whose timing of ART initiation was per strategy
had a higher CD4 count (151 cells/mm3 vs. 113 cells/mm3)
(P = 0.002) and a higher frequency of tolerating their TB
drugs (96% vs. 70%) (P < 0.0001) at the scheduled time of
ART initiation than did patients whose timing of ART initi-
ation was not per strategy.
Predictors of mortality in the first 6 months of TB
treatment
Results of predictive modeling of mortality are presented
in Table 2. In a series of crude (unadjusted) models, a CD4
count of <50 cells/mm3 (crude odds ratio (OR) = 6.0, 95% con-
fidence interval (CI): 2.2, 16.4) and TB treatment intolerance
Table 1. Baseline Characteristics of Participants by Timing of Antiretroviral Therapy Initiation per CD4-Stratified









No. % No. % No. %
Sex
Female 231 58.5 103 56.3 128 60.4 0.41
Male 164 41.5 80 43.7 84 39.6
Age, yearsa 38 (32–45) 38 (32–45) 38 (32–45) 0.97
Age, years
<30 65 16.5 32 17.5 33 15.6 0.61
30–39 158 40.0 73 39.9 85 40.1 0.97
40–49 129 32.7 56 30.6 73 34.4 0.42
≥50 43 10.9 22 12.0 21 9.9 0.50
Tuberculosis type
Smear positive, pulmonary 139 35.2 71 38.8 68 32.1 0.16
Smear negative, pulmonary 176 44.6 77 42.1 99 46.7 0.36
Extrapulmonary 80 20.3 35 19.1 45 21.2 0.60
CD4 count, cells/mm3a 131 (63–224) 151 (77–243) 113 (60–190) 0.002
CD4 count, cells/mm3
<50 77 19.5 33 18.0 44 20.8 0.50
50–99 64 16.2 21 11.5 43 20.3 0.02
100–199 136 34.4 61 33.3 75 35.4 0.67
200–350 118 29.9 68 37.2 50 23.6 0.003
Body mass indexa,b 17.8 (16.5–19.7) 17.7 (16.4–19.6) 17.8 (16.6–19.8) 0.35
Body mass indexb
Underweight (<18.5) 234 59.2 114 62.3 120 56.6 0.25
Normal (18.5–24.9) 148 37.5 64 35.0 84 39.6 0.34
Overweight (25.0–29.9) 11 2.8 4 2.2 7 3.3 0.56
Obese (≥30.0) 2 0.5 1 0.6 1 0.5 1.0
Toleration of tuberculosis drugs 322 81.5 175 95.6 147 69.3 <0.001
Contraindication to any ARV drug 24 6.1 7 3.8 17 8.0 0.09
WHO clinical stage 4 90 22.8 41 22.4 49 23.1 0.87
Abbreviations: ARV, antiretroviral; WHO, World Health Organization.
a Median (interquartile range).
b Weight (kg)/height (m)2.
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(crude OR = 12.3, 95% CI: 5.6, 27.3) were predictive of mor-
tality. In the final (reduced) model, TB treatment intolerance
(adjusted OR = 12.7, 95% CI: 4.8, 33.2), a CD4 count of
<50 cells/mm3 (adjusted OR = 7.3, 95% CI: 2.3, 23.3), and
male sex (adjusted OR = 2.4, 95% CI: 1.0, 5.6) were predic-
tive of mortality. In addition, underweight (adjusted OR =
2.2, 95% CI: 0.9, 5.6) and not initiating ART per strategy
(adjusted OR = 2.5, 95% CI: 0.9, 6.6) doubled the risk of
mortality, although not statistically significantly.
Mortality under observed implementation fidelity to
CD4-stratified ART initiation
During the first 6 months of TB treatment, 33 participants
died, and 47 (11.9%) were lost to follow-up. Among the 348
(88.1%) patients with an observed outcome, the 6-month
mortality risk was 9.5% (95% CI: 6.4, 12.6). The majority
(n = 26) of these deaths occurred in participants whose timing
of ART initiation deviated from the CD4-stratified strategy.
Table 2. Predictors of Mortality in 395 HIV- and TB-infected Participants Under Observed Implementation Fidelity to





Full Model Reduced Model
OR 95% CI OR 95% CI OR 95% CI
Sex
Male 1.78 0.86, 3.65 1.97 0.76, 5.09 2.37 1.00, 5.61
Female 1.00 Referent 1.00 Referent 1.00 Referent
Age, years
<30 1.36 0.44, 4.17 1.26 0.32, 4.96
30–39 1.00 Referent 1.00 Referent
40–49 1.72 0.71, 4.14 1.86 0.64, 5.37
≥50 2.40 0.82, 7.07 2.96 0.77, 11.40
Type of tuberculosis
Smear positive, pulmonary 1.00 Referent 1.00 Referent
Smear negative, pulmonary 2.01 0.81, 4.98 1.43 0.48, 4.24
Extrapulmonary 2.05 0.71, 5.91 1.11 0.07, 17.79
CD4 count, cells/mm3
<50 5.99 2.19, 16.36 7.66 2.27, 25.80 7.30 2.29, 23.30
50–99 1.81 0.53, 6.19 1.92 0.47, 7.86 1.94 0.49, 7.59
100–199 1.00 Referent 1.00 Referent 1.00 Referent
200–350 1.36 0.44, 4.17 2.19 0.58, 8.20 1.95 0.56, 6.79
Body mass indexa
Underweight (<18.5) 1.92 0.87, 4.27 2.46 0.94, 6.20 2.21 0.89, 5.62
Not underweight (≥18.5) 1.00 Referent 1.00 Referent 1.00 Referent
TB treatment intolerance
Yes 12.33 5.56, 27.31 12.75 4.69, 34.71 12.65 4.82, 33.20
No 1.00 Referent 1.00 Referent 1.00 Referent
Contraindication to any ARV
Yes 0.90 0.20, 4.04 1.43 0.48, 4.24
No 1.00 Referent 1.00 Referent
WHO stage
4 1.34 0.59, 3.01 1.28 0.10, 16.10
3 1.00 Referent 1.00 Referent
ART initiation
Not per strategy 4.25 1.79, 10.07 2.52 0.93, 6.86 2.47 0.93, 6.55
Per strategy 1.00 Referent 1.00 Referent 1.00 Referent
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; CI, confidence interval; HIV, human immunodeficiency
virus; OR, odds ratio; TB, tuberculosis; WHO, World Health Organization.
a Weight (kg)/height (m)2.
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When estimating the risk in the full cohort (i.e., including
those lost to follow-up) using the predicted outcome proba-
bilities from the logistic regression model, we found that the
6-month mortality risk under observed implementation fidel-
ity was 12.0% (95% CI: 8.2, 15.7).
Estimated causal effect of implementation fidelity on
6-month mortality
As shown in Table 3, complete fidelity to the CD4-stratified
timing strategy for ART initiation in this population was esti-
mated to result in a 6-month mortality risk of 7.8% (95% CI:
2.4, 12.3), corresponding to a −4.2% risk difference (95% CI:
−8.1, −0.3). The preventable fraction of mortality due to non-
fidelity to the CD4-stratified ART initiation strategy was 35.1%
(95% CI: 2.9, 67.9), suggesting that just over one third of the
mortality is preventable by complete implementation fidelity.
These mortality estimates were robust to sensitivity analyses
in which the definition of ART initiation per strategy was nar-
rowed to exclude patients whowere lost to follow-up prior to the
time of eligibility (risk difference,−4.1%, 95%CI:−7.8,−0.5),
and the preventable fraction was 34.6% (95% CI: 3.8, 65.3).
DISCUSSION
Despite full integration of TB treatment and ART, only
46% of all HIV-infected TB patients initiated ART per CD4-
stratified timing strategy (i.e., within 1–2 months of TB treat-
ment initiation). The remaining 54% of patients either failed
to start or experienced a median additional delay of 11 (IQR,
4–24) days. We estimated that, if these failures to initiate and
delays could be avoided, the 6-month mortality risk would
fall by 4.2%, representing a 35.1% preventable fraction of
mortality in this population. These findings suggest that strat-
egies are needed to improve the implementation of the 2012
WHO recommendation that calls for CD4-stratified timing of
ART initiation (5).
Under the condition of low (46%) implementation fidelity
to the CD4-stratified ART initiation strategy, the 6-month
estimated mortality risk in the full cohort was 12.0%. This
estimated risk was higher than the observed risk (9.5%), be-
cause patients whowere lost to follow-up and missing an out-
come had a high risk of mortality based on their baseline
characteristics. Although not unexpected given the many
common risk factors for lost to follow-up and mortality, this
demonstrates that a complete-case analysis may underesti-
mate mortality risk. Under the scenario of 100% fidelity to
the CD4 count–stratified ART initiation strategy, we found a
4.2% (95%CI: 0.03, 8.1) reduction inmortality risk, represent-
ing a 35.1% preventable fraction of mortality. Interventions
aimed at factors associated with deviation from CD4-stratified
timing are thus needed to improve implementation fidelity
(21). However, even under complete implementation fidelity,
there were 10 patients whose predicted probability of death
was greater than 50%. All 10 had a baseline CD4 count of <50
cells/mm3 and did not tolerate TB treatment, suggesting that
interventions other than improving implementation fidelity
to CD4-stratified ART initiation may be needed to prevent
their death. Because the definition of TB treatment intolerance
is inherently nonspecific, patients with severe immunosuppres-
sion who are assessed as not tolerating TB treatment may, in
fact, have other underlying clinical conditions that contribute
to mortality and require attention beyond that available at the
primary care level. In fact, many factors likely contribute to
mortality in our population; we focused our analysis on the
timing of ART initiation.
Few studies have quantified implementation fidelity to
international guidelines for resource-limited settings, and
we are not aware of any studies attempting to estimate the in-
cremental gain achievable through 100% implementation
fidelity. As such, it remains unclear whether any positive out-
comes following implementation of new guidelines would be
improved further if greater attention were paid to implemen-
tation fidelity. It has therefore been suggested that, to discern
the true impact of an intervention, research should evaluate
implementation fidelity (13).
Our study provides 1 of the first examples of using modern
epidemiologic methods to measure the impact of implemen-
tation fidelity on desired outcomes. The parametric g-formula
generates unbiased estimates of the causal effect of an inter-
vention by using observational data when assumptions of ex-
changeability (no uncontrolled confounding or uncontrolled
selection bias), positivity (patients in each treatment group
across all strata of each covariate), and consistency (for a
given treatment, the counterfactual outcome is equivalent to
the observed outcome for each patient) are met. This allows
investigators to extend the analysis of observational study
beyond the traditional all versus none comparison and, in-
stead, estimate the population-attributable risk difference
Table 3. Six-Month Mortality Risk Under Observed and Complete
Implementation Fidelity to Timing of Antiretroviral Therapy Initiation
per CD4-Stratified Strategy, Integrating Tuberculosis and Antiretroviral
Treatment Study, 2007–2009
Estimate 95% CI
Risks in ITART Study population
(n = 395)
Observed riska 0.095 0.064, 0.126
Estimated (modeled) risk under
observed implementation fidelity
to the CD4-stratified ART
initiation strategyb
0.120 0.082, 0.157
Estimated risk under complete





Estimated risk difference inmortality
between observed and complete
implementation fidelityb
−0.042 −0.081, −0.003




Abbreviation: ART, antiretroviral therapy; CI, confidence interval;
ITART, Integrating Tuberculosis and Antiretroviral Treatment.
a Excludes 47 patients missing 6-month mortality outcome.
b Includes estimated/predicted outcomes for those missing 6-month
mortality outcome.
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and fraction,which contrast counterfactual scenarios ofmore
relevance.We used this approach to study the risk difference
between different levels (observed vs. 100%) of implemen-
tation fidelity to 1 intervention. This approach could also be
used to compare the estimated impact of multiple or complex
interventions (18, 20, 22). We therefore believe that the appli-
cation of the parametric g-formula has great potential to con-
tribute to the field of implementation science (22, 23).
Our study has several limitations that must be considered.
First, the nursesmaking decisions onART timingwere trained
and closely monitored as part of the study. Implementation
fidelity may be even lower in routine settings, and our esti-
mates of the causal effect of implementation fidelity may
therefore be an underestimate. Second, similar to most imple-
mentation fidelity studies, our assessment focused exclusively
on the adherence component by assessing whether ART was
initiated on time. We did not evaluate other components of
implementation fidelity, such as intervention complexity, fa-
cilitation strategies, quality of delivery, and patient responsive-
ness, which can influence or moderate the level of adherence
to guideline implementation by health-care workers (13).
Third, because of limited follow-up data, we focused on re-
duction in short-term mortality, which is only one of the de-
sired outcomes of TB/HIV care. Other potentially relevant
outcomes include long-term mortality, medication adher-
ence, and biologically confirmed treatment success. Finally,
although we adjusted for baseline covariates identified as po-
tential confounders, we cannot exclude the possibility of re-
sidual confounding.
In conclusion, despite full integration of TB treatment and
ART, delayed initiation of ART continues to occur and re-
sults in increased mortality risk. Strategies to achieve high
implementation fidelity to CD4-stratified timing of ART initi-
ation for patients with TB at primary-care clinics in resource-
limited settings are thus needed.
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APPENDIX 1
Steps of the Parametric g-Formula to Estimate the Risk Difference Between the Observed and Complete
Implementation Fidelity to Timing of ART Initiation per CD4-Stratified Strategy
1. Fit a logistic regression model of the association between initiating ART per strategy and mortality, including confounders
derived from a causal directed acyclic graph.
2. Use parameter estimates from the model to estimate predicted probabilities of death for each patient on the basis of their base-
line factors and observed ART timing.
3. Estimate the risk of death in the ITART Study population with observed fidelity to ART timing per CD4-stratified strategy, by
taking the average of the predicted probabilities of death calculated in step 2 across all patients.
4. Recalculate the predicted probabilities for each patient under the scenario of complete fidelity to ART timing per
CD4-stratified strategy.
5. Estimate the risk of death in the ITART Study population with complete fidelity to ART timing per CD4-stratified strategy, by
taking the average of the predicted probabilities of death calculated in step 4 across all patients.
6. Estimate the risk difference by subtracting the average risk of death in the ITART Study population with complete fidelity
(step 5) from the average risk of death in the same study population with observed fidelity (step 3).
7. Estimate the 95% confidence interval through bootstrap estimation: Create multiple (B) data sets through random selection
with replacement from the original ITART Study population, rerun steps 1–6 on each data set to estimate B risk differences,
and use the standard deviation of the B risk differences to estimate the standard error of the original point estimate.
APPENDIX 2
Application of the Parametric g-Formula to Estimate the Risk Difference Between Observed and Complete Fidelity
to CD4-Stratifed Timing of ART Initiation
We used logistic regression and the parametric g-formula to calculate the predicted probability of death for each patient in the
analytical population of 395 patients under 2 scenarios of implementation of the CD4-stratified timing strategy for ART initia-
tion: scenario 1 (observed fidelity) and scenario 2 (complete fidelity).
As an example, we applied this method for patient X, who was 32 years of age, diagnosed with smear-positive pulmonary TB,
tolerating TB treatment, andWHO stage 3; whose ART initiation was not per strategy; who had a CD4 count of 45 cells/mm3 and
an underweight body mass index of <18.5; and who did not have any contraindication to antiretroviral drugs.
The logistic regression model, which includes a variable corresponding to whether the patient initiated ART per strategy and
covariates included in Table 1, generated regression parameters such that
Ln½PðD¼ 1jX¼ xÞ ¼ 2:6590þ 0:0305ðageÞþ0:6731ðfemaleÞ
þ0:9064ðper strategyÞþ2:5365ðtb tx toleratedÞ
þ 2:0222ðcd4 less 50Þþ 0:6315ðcd4 50 99Þ
þ 0:7738ðcd4 200 350Þþ 0:2346ðcontraindicationÞ
þ 0:3727ðsmear negÞþ 0:0296ðextrapulmonaryÞ
þ 0:3744ðwho 4Þþ 0:8832ðunderweightÞ:
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Scenario 1: observed fidelity to CD4-stratified strategy for timing of ART initiation
As shown in the calculation below, for patient X, the (factual) predicted probability of death under his observed fidelity to ART
timing was 21%:
Ln½PðD¼ 1jX¼ xÞ ¼2:6590þ 0:0305ð32Þþ0:6731ð0Þþ0:9064ð0Þ
þ2:5365ð1Þþ 2:0222ð1Þþ 0:6315ð0Þþ 0:7738ð0Þ
þ 0:2346ð0Þþ 0:3727ð0Þþ 0:0296ð0Þþ 0:3744ð0Þþ 0:8832ð1Þ
Ln½PðD¼ 1jX¼ xÞ¼ 1:3141
PðD¼ 1jX¼ xÞ¼ ½expð1:3141Þ=½1þ expð1:3141Þ ¼ 0:212:
Scenario 2: complete fidelity to CD4-stratified timing of ART initiation
In order to estimate the (counterfactual) predicted probability of death for patient X under complete fidelity to ART timing,
we used the same regression parameters and baseline characteristics; however, we enter a “1” instead of a “0” for the coefficient
corresponding to the regression parameter for ART per strategy. As shown in the calculation below, for patient X, the predicted
probability of death under complete fidelity was 9.5%:
Ln½PðD¼ 1jX¼ xÞ ¼2:6590þ 0:0305ð32Þþ0:6731ð0Þþ0:9064ð1Þ
þ2:5365ð1Þþ 2:0222ð1Þþ 0:6315ð0Þþ 0:7738ð0Þþ 0:2346ð0Þ
þ 0:3727ð0Þþ 0:0296ð0Þþ 0:3744ð0Þþ 0:8832ð1Þ
Ln½PðD¼ 1jX¼ xÞ ¼ 2:2205
PðD¼ 1jX¼ xÞ¼ ½expð2:251Þ=½1þ expð2:251Þ ¼ 0:098:
From this example, it is clear that, for patients (unlike this one) whose observed ART initiation was per strategy, the predicted
probability under complete fidelity (scenario 2) would be the same as the predicted probability under observed fidelity (sce-
nario 1).
To estimate the population risk under observed and complete fidelity, we took the average of the individual patient probabilities of
death under scenario 1 and the average of the individual population probabilities of death under scenario 2. Then, we subtracted the
average population risk under scenario 2 from the average population risk under scenario 1 to calculate the risk difference, as ameasure
of effect of complete implementation fidelity compared with observed implementation fidelity. The 95% confidence interval was
bootstrapped by sampling with replacement from the original analytical population to generate 500 data sets (n = 395). In each
data set, we estimated the risk difference and then used the standard deviation across these 500 estimates to estimate the 95% con-
fidence interval around the risk difference from the original analytical population.
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